In vitro approaches to studying the metabolism of new psychoactive compounds

Drug Testing and Analysis

Volumn 3, Issue 7-8, 2011, Pages 483-495

  Peters, Frank T ^a   Meyer, Markus R ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cytosol; Drug; Hepatocyte; Microsome; S9 mix

Indexed keywords

COMMERCE; DRUG PRODUCTS; ENZYMES; MASS SPECTROMETRY; PHYSIOLOGY; RISK ASSESSMENT;

ANALYTICAL METHOD DEVELOPMENT; CYTOSOLS; DESIGNER DRUGS; DRUG; DRUG MARKETS; HEPATOCYTES; ILLICIT DRUG; IN-VITRO; MICROSOME; S9 MIX;

METABOLISM;

2,4,5 TRIMETHOXYAMPHETAMINE; 2,5 DIMETHOXY 4 CHLOROAMPHETAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3 CHLORO PHENYLPIPERAZINE; 3 TRIFLUOROMETHYL PHENYLPIPERAZINE; 3',4' METHYLENEDIOXY PYROVALERONE; 3,4 METHYLENEDIOXY BENZYLPIPERAZINE; 4 BROMO 2,5 DIMETHOXY PHENETHYLAMINE; 4 ETHYL 2,5 DIMETHOXY PHENETHYLAMINE; 4 ETHYLTHIO 2,5 DIMETHOXY PHENETHYLAMINE; 4 IODO 2,5 DIMETHOXY PHENETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4 METHOXY METHAMPHETAMINE; 4 METHOXY PHENYLPIPERAZINE; 4 METHYL 2,5 DIMETHOXY PHENETHYLAMINE; 4 METHYLTHIO AMPHETAMINE; 4 PROPYL 2,5 DIMETHOXY PHENETHYLAMINE; 4 PROPYLTHIO 2,5 DIMETHOXY PHENETHYLAMINE; 4' METHOXYPYRROLIDINOPROPIOPHENONE; 4' METHYLPYRROLIDINOHEXANOPHENONE; 4' METHYLPYRROLIDINOPROPIOPHENONE; 5 METHOXY N,N DIISOPROPYLTRYTAMINE; BROLAMFETAMINE; N (1 PHENYLCYCLOHEXYL) 3 ETHOXYETHANAMINE; N (1 PHENYLCYCLOHEXYL) 3 ETHOXYPROPANAMINE; N (1 PHENYLCYCLOHEXYL) 3 METHOXYETHANAMINE; PSYCHOTROPIC AGENT; PYRROLIDINOVALEROPHENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; BIOTRANSFORMATION; CARCINOGENICITY; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENANTIOMER; ENZYME MECHANISM; ENZYME METABOLISM; FOOD DRUG INTERACTION; GLUCURONIDATION; GLUTATHIONE METABOLISM; HUMAN; HYDROXYLATION; IN VITRO STUDY; LIVER CELL; LIVER CYTOSOL; LIVER MICROSOME; LIVER TOXICITY; MASS SPECTROMETRY; MUTAGENICITY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH ENDOPLASMIC RETICULUM;

EID: 79960641733     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.295     Document Type: Review

References (76)

1. US Department of Health and Human Services. Guidance for Industry: Safety Testing of Drug Metabolites, 2008, Available at: .
2. R. F. Staack, H. H. Maurer. Metabolism of designer drugs of abuse. Curr. Drug Metab. 2005, 6, 259.
3. M. R. Meyer, H. H. Maurer. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 2010, 11, 468.
4. M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, D. C. Zeldin. The human intestinal cytochrome P450 'pie'. Drug Metab. Dispos. 2006, 34, 880.
5. H. Raunio, J. Hakkola, J. Hukkanen, O. Pelkonen, R. Edwards, A. Boobis, S. Anttila, Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch. Toxicol. Suppl. 1998, 20, 465.
6. D. F. Lewis. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004, 5, 305.
7. A. Wintermeyer, I. Möller, M. Thevis, M. Jübner, J. Beike, M. A. Rothschild, K. Bender. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 2010, 398.
8. J. Bickeboeller-Friedrich, H. H. Maurer. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001, 23, 61.
9. R. F. Staack, D. S. Theobald, L. D. Paul, D. Springer, T. Kraemer, H. H. Maurer. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. Drug Metab. Dispos. 2004, 32, 379.
10. R. F. Staack, L. D. Paul, D. Springer, T. Kraemer, H. H. Maurer. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in wistar and dark agouti rats as well as in vitro studies in human liver microsomes. Biochem. Pharmacol. 2004, 67, 235.
11. R. F. Staack, D. S. Theobald, L. D. Paul, D. Springer, T. Kraemer, H. H. Maurer. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 2004, 34, 179.
12. D. Springer, L. D. Paul, R. F. Staack, T. Kraemer, H. H. Maurer. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab. Dispos. 2003, 31, 979.
13. F. T. Peters, M. R. Meyer, D. S. Theobald, H. H. Maurer. Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone. Drug Metab. Dispos. 2008, 36, 163.
14. D. Springer, R. F. Staack, L. D. Paul, T. Kraemer, H. H. Maurer. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica 2003, 33, 989.
15. D. Springer, R. F. Staack, L. D. Paul, T. Kraemer, H. H. Maurer. Identification of cytochrome P450 enzymes involved in the metabolism of 3', 4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes. Xenobiotica 2005, 35, 227.
16. C. Sauer, F. T. Peters, A. E. Schwaninger, M. R. Meyer, H. H. Maurer. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxy-propanamine. Chem. Res. Toxicol. 2008, 21, 1949.
17. C. Sauer, F. T. Peters, A. E. Schwaninger, M. R. Meyer, H. H. Maurer. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem. Pharmacol. 2009, 77, 444.
18. C. Sauer, F. T. Peters, C. Haas, M. R. Meyer, G. Fritschi, H. H. Maurer. New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2009, 44, 952.
19. M. R. Meyer, P. Du, F. Schuster, H. H. Maurer. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution-MS and its detectability in urine by GC-MS. J. Mass Spectrom. 2010, 45, 1426.
20. A. H. Ewald, M. Puetz, H. H. Maurer. Designer drug 2, 5-dimethoxy-4-methyl-amphetamine (DOM, STP): involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 862, 252.
21. A. H. Ewald, H. H. Maurer. 2, 5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol. Lett. 2008, 183, 52.
22. D. S. Theobald, H. H. Maurer. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem. Pharmacol. 2007, 73, 287.
23. S. Narimatsu, R. Yonemoto, K. Saito, K. Takaya, T. Kumamoto, T. Ishikawa, M. Asanuma, M. Funada, K. Kiryu, S. Naito, Y. Yoshida, S. Yamamoto, N. Hanioka. Oxidative metabolism of 5-methoxy-N, N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem. Pharmacol. 2006, 71, 1377.
24. Z. S. Teksin, I. J. Lee, N. N. Nemieboka, A. A. Othman, V. V. Upreti, H. E. Hassan, S. S. Syed, T. E. Prisinzano, N. D. Eddington. Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. Eur. J. Pharm. Biopharm. 2009, 72, 471.
25. M. R. Meyer, H. H. Maurer. Current knowledge of the isoenzymes involved in the metabolism and transport of frequently abused opioids, anesthetics, cognitive enhancers, plant-derived hallucinogens, and of nicotine with aspects on pharmacogenomics. Pharmacogenomics 2011, 12, 215.
26. M. R. Meyer, F. T. Peters, H. H. Maurer. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3, 4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab. Dispos. 2008, 36, 2345.
27. M. R. Meyer, F. T. Peters, H. H. Maurer. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3, 4-methylenedioxyethylamphetamine and its single enantiomers. Drug Metab. Dispos. 2009, 37, 1152.
28. M. R. Meyer, F. T. Peters, H. H. Maurer. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem. Pharmacol. 2009, 77, 17.
29. M. R. Meyer, F. T. Peters, H. H. Maurer. Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3, 4-methylenedioxy-amphetamine (MDA) and benzodi-oxolyl-butanamine (BDB) enantiomers. Toxicol. Lett. 2009, 190, 54.
30. S. K. Krueger, D. E. Williams. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 2005, 106, 357.
31. J. R. Cashman. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr. Drug Metab. 2000, 1, 181.
32. R. L. Haining, A. P. Hunter, A. J. Sadeque, R. M. Philpot, A. E. Rettie. Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization. Drug Metab. Dispos. 1997, 25, 790.
33. I. M. Hisamuddin, V. W. Yang. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007, 8, 635.
34. I. R. Phillips, C. T. Dolphin, P. Clair, M. R. Hadley, A. J. Hutt, R. R. McCombie, R. L. Smith, E. A. Shephard. The molecular biology of the flavin-containing monooxygenases of man. Chem. Biol. Interact. 1995, 96, 17.
35. S. K. Lee, M. J. Kang, C. Jin, M. K. In, D. H. Kim, H. H. Yoo. Flavin-containing monooxygenase 1-catalysed N, N-dimethyl-amphetamine N-oxidation. Xenobiotica 2009, 39, 680.
36. A. Radominska-Pandya, P. J. Czernik, J. M. Little, E. Battaglia, P. I. Mackenzie. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab. Rev. 1999, 31, 817.
37. R. H. Tukey, C. P. Strassburg. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581.
38. M. Kurkela, J. A. Garcia-Horsman, L. Luukkanen, S. Morsky, J. Taskinen, M. Baumann, R. Kostiainen, J. Hirvonen, M. Finel. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem. 2003, 278, 3536.
39. T. Kuuranne, M. Kurkela, M. Thevis, W. Schanzer, M. Finel, R. Kostiainen. Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2003, 31, 1117.
40. A. Mazur, C. F. Lichti, P. L. Prather, A. K. Zielinska, S. M. Bratton, A. Gallus-Zawada, M. Finel, G. P. Miller, A. Radominska-Pandya, J. H. Moran. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab. Dispos. 2009, 37, 1496.
41. A. E. Schwaninger, M. R. Meyer, J. Zapp, H. H. Maurer. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase II metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metab. Dispos. 2009, 37, 2212.
42. J. Barsky, W. L. Pacha, S. Sarkar, E. A. Zeller. Amine oxidases. XVII. Mode of action of 1-isonicotinyl-2-isopropylhydrazine on monoamine oxidase. J. Biol. Chem. 1959, 234, 389.
43. D. E. Edmondson, A. Mattevi, C. Binda, M. Li, F. Hubalek. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11, 1983.
44. M. D. Berry, A. V. Juorio, I. A. Paterson. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog. Neurobiol. 1994, 42, 375.
45. H. Glatt, W. Meinl. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 55.
46. H. Glatt, H. Boeing, C. E. Engelke, L. Ma, A. Kuhlow, U. Pabel, D. Pomplun, W. Teubner, W. Meinl. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 2001, 482, 27.
47. A. E. Schwaninger, M. R. Meyer, J. Zapp, H. H. Maurer. Sulfation the 3, 4-methylenedioxymethamphetamine (MDMA) metabolites 3, 4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol. Lett. 2011, 202, 120.
48. R. F. Staack, G. Fritschi, H. H. Maurer. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 773, 35.
49. R. F. Staack, H. H. Maurer. New designer drug 1-(3, 4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 2004, 39, 255.
50. M. R. Meyer, H. H. Maurer. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem. Res. Toxicol. 2009, 22, 1205.
51. C. A. Aiub, L. F. Pinto, I. Felzenszwalb. Standardization of conditions for the metabolic activation of N-nitrosodiethylamine in mutagenicity tests. Genet. Mol. Res. 2004, 3, 264.
52. J. W. Allen, R. Langenbach, S. Nesnow, K. Sasseville, S. Leavitt, J. Campbell, K. Brock, Y. Sharief. Comparative genotoxicity studies of ethyl carbamate and related chemicals: further support for vinyl carbamate as a proximate carcinogenic metabolite. Carcinogenesis 1982, 3, 1437.
53. M. Otto, S. H. Hansen, L. Dalgaard, J. Dubois, L. Badolo. Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Cell Biol. Toxicol. 2008, 24, 87.
54. S. Strano-Rossi, A. B. Cadwallader, X. de la Torre, F. Botre. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24, 2706.
55. R. Laine. Metabolic stability: main enzymes involved and best tools to assess it. Curr. Drug Metab. 2008, 9, 921.
56. A. P. Li, C. Lu, J. A. Brent, C. Pham, A. Fackett, C. E. Ruegg, P. M. Silber. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 1999, 121, 17.
57. J. G. Hengstler, D. Utesch, P. Steinberg, K. L. Platt, B. Diener, M. Ringel, N. Swales, T. Fischer, K. Biefang, M. Gerl, T. Bottger, F. Oesch. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab. Rev. 2000, 32, 81.
58. H. Carmo, J. G. Hengstler, D. de Boer, M. Ringel, F. Carvalho, E. Fernandes, F. Remiao, L. A. dos Reys, F. Oesch, M. de Lourdes Bastos. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 198.
59. H. Carmo, J. G. Hengstler, D. de Boer, M. Ringel, F. Remiao, F. Carvalho, E. Fernandes, L. A. dos Reys, F. Oesch, M. de Lourdes Bastos. Metabolic pathways of 4-bromo-2, 5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 2005, 206, 75.
60. C. L. Crespi, V. P. Miller. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther. 1999, 84, 121.
61. K. Grime, R. J. Riley. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr. Drug Metab. 2006, 7, 251.
62. K. Venkatakrishnan, L. L. von Moltke, M. H. Court, J. S. Harmatz, C. L. Crespi, D. J. Greenblatt. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 2000, 28, 1493.
63. K. Venkatakrishnan, L. L. von Moltke, D. J. Greenblatt. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 2001, 297, 326.
64. K. Venkatakrishnan, L. L. Von Moltke, D. J. Greenblatt. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 2001, 41, 1149.
65. C. L. Crespi. Advances in Drug Research, Vol. 26 (Eds: B. Testa, U. A. Meyer ). Academic Press: London, 1995, pp. 179-235.
66. K. Rouguieg, N. Picard, F. L. Sauvage, J. M. Gaulier, P. Marquet. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 2010, 38, 40.
67. C. Sauer, F. T. Peters, R. F. Staack, G. Fritschi, H. H. Maurer. New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2008, 43, 305.
68. A. A. Philipp, D. K. Wissenbach, S. W. Zoerntlein, O. N. Klein, J. Kanogsunthornrat, H. H. Maurer. Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. J. Mass Spectrom. 2009, 44, 1249.
69. C. A. Dragan, F. T. Peters, P. Bour, A. E. Schwaninger, S. M. Schaan, I. Neunzig, M. Widjaja, J. Zapp, T. Kraemer, H. H. Maurer, M. Bureik. Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems. Appl. Biochem. Biotechnol. 2011, 163, 965.
70. F. T. Peters, C. A. Dragan, D. R. Wilde, M. R. Meyer, J. Zapp, M. Bureik, H. H. Maurer. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone. Biochem. Pharmacol. 2007, 74, 511.
71. F. T. Peters, A. E. Schwaninger, C. A. Dragan, C. Sauer, G. Fritschi, M. Bureik, H. H. Maurer. Isolation and purification of the designer drug metabolite O-Deethyl-(1-phenylcyclohexyl)-3-ethoxypropanamine (O-Deethyl-PCEPA)-Biotechnologically synthesized using fission yeast expressing CYP2D6, in Current Contributions to Forensic and Clinical Toxicology, Proceedings of the XVth GTFCh Symposium, Mosbach, Germany, 18-21 April 2007. (Eds.: F. Pragst, R. Aderjan ), GTFCH, Bad Vilbel: Germany, 2008, pp. 204-210.
72. F. T. Peters, C. A. Dragan, A. E. Schwaninger, C. Sauer, J. Zapp, M. Bureik, H. H. Maurer. Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. Forensic Sci. Int. 2009, 184, 69.
73. F. T. Peters, M. Bureik, H. H. Maurer. Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. Bioanalysis 2009, 1, 821.
74. A. Zollner, D. Buchheit, M. R. Meyer, H. H. Maurer, F. T. Peters, M. Bureik. Production of human phase 1 and 2 metabolites by whole-chell biotransformation with recombinant microbes. Bioanalysis 2010, 2, 1277.
75. T. Shoda, K. Fukuhara, Y. Goda, H. Okuda. 4-Hydroxy-3-methoxymethamphetamine glucuronide as a phase II metabolite of 3, 4-methylenedioxymethamphetamine: enzyme-assisted synthesis and involvement of human hepatic uridine 5'-diphosphate-glucuronosyltransferase 2B15 in the glucuronidation. Chem. Pharm. Bull. (Tokyo) 2009, 57, 472.
76. S. C. Turfus, M. C. Parkin, D. A. Cowan, J. M. Halket, N. W. Smith, R. A. Braithwaite, S. P. Elliot, G. B. Steventon, A. T. Kicman. Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab. Dispos. 2009, 37, 1769.